Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule

1995 ◽  
Vol 35 (6) ◽  
pp. 483-488 ◽  
Author(s):  
James R. Rigas ◽  
Prudence A. Francis ◽  
Vincent A. Miller ◽  
William P. Tong ◽  
Nancy Roistacher ◽  
...  
Keyword(s):  
Weekly Schedule ◽  
Chloroquinoxaline Sulfonamide

Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule

1995 ◽  
Vol 35 (6) ◽  
pp. 483-488
Author(s):  
James R. Rigas ◽  
J. R Rigas P. A. Francis ◽  
Vincent A. Miller ◽  
William P. Tong ◽  
Nancy Roistacher ◽  
...  
Keyword(s):  
Weekly Schedule ◽  
Chloroquinoxaline Sulfonamide

Developing the culture and discipline of conducting and publishing scientific research: Guiding principles

2014 ◽  
Vol 1 ◽  
pp. 1-7
Author(s):  
Daniel Obeng-Ofori
Keyword(s):  
Developing Countries ◽  
Scientific Research ◽  
Scientific Writing ◽  
Weekly Schedule ◽  
Academic Activities ◽  
Heavy Workload ◽  
Guiding Principles ◽  
Mentoring System ◽  
Critical Constraints

The pressure to publish is a fact of life in academia. Academics are expected to demonstrate that they are active researchersand that their work has been vetted by peers and disseminated in reputable scholarly forums. In practice, however, a numberof critical constraints hamper effective publication of scientific research in most developing countries. These include lackof effective mentoring system, poor facilities and inadequate funding for effective research and heavy workload where toomuch time and effort are spent in teaching, grading, meetings and other non-academic activities. In spite of these seeminglyinsurmountable challenges, with proper planning and commitment, one can still conduct research and publish to advanceones career and exchange of knowledge. The paper discusses the critical guiding principles in scientific writing and publishingin an unfriendly research environment as pertains in most universities in the developing world. The overriding principle isto cultivate the discipline of scientific writing consciously and follow it through religiously. This could be achieved if time isallocated for scientific writing in the scheme of weekly schedule of activities and made to be functional through meticulousplanning and commitment. Equally important is to avoid procedural mistakes in scientific writing. While the quality of theresearch is the single most important factor in determining whether an article will be published, a number of proceduralmistakes can help tip the balance against its publication. It should also be noted that when a manuscript is submitted to ascholarly journal, there are two audiences to satisfy: first the editor and external reviewers, and then the journal’s readers.That first group must be satisfied to create the opportunity to appeal to the second. Thus, familiarity with the style and tone ofthe specific journal is crucial.

scholarly journals Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

2019 ◽  
Vol 12 (1) ◽  
pp. 84-90 ◽  
Author(s):  
Nobuhiko Seki ◽  
Ryosuke Ochiai ◽  
Terunobu Haruyama ◽  
Masashi Ishihara ◽  
Maika Natsume ◽  
...  
Keyword(s):  
Substance P ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Stage Iv ◽  
Subsequent Treatment ◽  
Treatment Schedule ◽  
Weekly Schedule ◽  
Patient Centered ◽  
Neurokinin 1 ◽  
Dermatological Side Effects

Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer treatment. Aprepitant is an antagonist of neurokinin-1 receptor, through which substance P activates the pruritogens. Thus, aprepitant is expected to offer a promising option for the treatment of erlotinib-induced pruritus. However, the appropriate treatment schedule for aprepitant administration is under consideration. Here, we discuss the need for flexible adjustment of the treatment schedule for aprepitant administration against erlotinib-induced refractory pruritus and skin rush. A 71-year-old female smoker presented with stage IV EGFR-mutated lung adenocarcinoma. She was started on erlotinib at 150 mg/day. However, by 28 days, severe pruritus and acneiform skin rush resistant to standard therapies occurred, resulting in the interruption of erlotinib therapy. After recovery, she was restarted on erlotinib at 100 mg/day. However, severe pruritus and skin rush developed again within 2 weeks. Then, we started the first 3-day dose of aprepitant (125 mg on day 1, 80 mg on day 3, and 80 mg on day 5) based on the results of the previous prospective study, which showed the success rate of 100% with at least the second dose of aprepitant. However, the pruritus and skin rush exacerbated again within 4 weeks. Therefore, we started the second 3-day dose of aprepitant, but in vain. At this point, as the patient-centered medicine, bi-weekly schedule of the 3-day dose of aprepitant was considered and, then, adopted. As the results, the pruritus and skin rush remained well-controlled throughout the subsequent treatment with erlotinib.

Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule

2003 ◽  
Vol 52 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Xiao-Du Guo ◽  
Nancy Harold ◽  
M. Wasif Saif ◽  
Barbara Schuler ◽  
Eva Szabo ◽  
...  
Keyword(s):  
Weekly Schedule ◽  
Pharmacodynamic Effects

Phase I Trial and Biochemical Evaluation of Tiazofurin Administered on a Weekly Schedule

1990 ◽  
Vol 6 (1) ◽  
pp. 51-61 ◽  
Author(s):  
TERESA J. MELINK ◽  
GISELE SAROSY ◽  
AXEL-R. HANAUSKE ◽  
JERRY L. PHILLIPS ◽  
JOANNE H. BAYNE ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Weekly Schedule ◽  
Biochemical Evaluation

A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck

1993 ◽  
Vol 29 (9) ◽  
pp. 1358-1359 ◽  
Author(s):  
Vittorio Gebbia ◽  
Antonio Testa ◽  
Roberto Valenza ◽  
Giuseppe Zerillo ◽  
Salvatore Restivo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Pilot Study ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Weekly Schedule ◽  
Metastatic Squamous Cell Carcinoma

MO843PREVALENCE AND MANAGEMENT OF HYPERTENSION IN HEMODIALYSIS PATIENTS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Ali AlSahow ◽  
Anas Alyousef ◽  
Bassam Alhelal ◽  
Heba AlRajab ◽  
Yousif Bahbahani ◽  
...  
Keyword(s):  
Weight Gain ◽  
Fluid Intake ◽  
Salt Intake ◽  
Statistical Significance ◽  
Dry Weight ◽  
Weekly Schedule ◽  
Interdialytic Weight Gain ◽  
High Salt Intake ◽  
Number Of Patients ◽  
High Calcium

Abstract Background and Aims Hypertension (HTN) is common in hemodialysis (HD) patients & diagnosed by pre-dialysis BP >140/90 mmHg. Causes include high salt intake, volume overload, & loss of residual kidney function. Therapy includes achieving correct dry weight with each session, restricting interdialytic sodium & fluid intake & medications. We review its prevalence, factors associated with it & its management in our patients. Method Demographics, HD prescription & medications data collected for patients from 5 dialysis centers. Results A total of 1585 files reviewed. Males were 51.8% & mean age was 59. Mean age significantly higher for females (61 vs 57). ESKD cause was DM in 51% & HTN in 35%. However, of files reviewed, adequate data on comorbidities in 1390 patients (table 1), 69% had DM, 92% had HTN, 47% had CVD & 31% had BMI > 25 (which was significantly more frequent in females). HTN was more likely in older patients, diabetics & females with odds of HTN in females nearly twice the odds of HTN in males & odds of HTN with DM is 2.27 times odds of HTN without DM & one-year increase in age would increase odds of HTN by nearly 4%. Mean pre-HD BP for those with HTN was 143/76 mmHg & for those without HTN was 136/75 mmHg. HD frequency was thrice weekly in 94% & HD duration was > 3.5 hours in only 77% of patients. HDF used in 81.5%. Mean interdialytic weight gain (IDWG) was 2.8 kg, with no difference according to gender or presence of DM or HTN (Table 2). Higher IDWG associated with age < 65, Calcium bath of 1.75 & Sodium bath > 138 with 0.638 kg higher IDWG with calcium of 1.75 compared to calcium of 1.25. Higher IDWG was associated with higher BP. Mean volume of fluid removed per session was 2.74, which was less than mean IDWG, with no difference according to gender or DM, however, it was higher in the higher dialysate sodium group, & lower in the shorter session group (with trend towards statistical significance). CCB used to treat HTN in 62% followed by βB in 52%. Number of patients with HTN on 1 drug 21%, 2 drugs 27%, 3 drugs 23%, ≥ 4 drugs 20% & 9% missing data. Number of antihypertensives did not correlate with IDWG. Conclusion Interdialytic weight gain in our HD patients is excessive & contributing to HTN. Patients must restrict salt & fluid intake & dialysis centers must regularly & frequently assess dry weight, ensure thrice weekly schedule & 4 hours per session are met, so excess fluid is completely removed. Also, high sodium & high calcium baths need to be avoided.

Phase I evaluation of SOAz (1,3,3,5,5Pentakis(aziridino)-1λ6,2,4,6,3λ5,5λ5thiatriaza-diphosphorine-1-oxide) in a weekly schedule

1984 ◽  
Vol 20 (5) ◽  
pp. 645-649 ◽  
Author(s):  
Sjoerd Rodenhuis ◽  
Nanno H. Mulder ◽  
Dirk TH. Sleijfer ◽  
Helmen Schraffordt Koops ◽  
Johan C. van de Grampel
Keyword(s):  
Phase I ◽  
Weekly Schedule

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS8055-TPS8055
Author(s):  
Hang Quach ◽  
Masa Lasica ◽  
David Routledge ◽  
Anna Kalff ◽  
Andrew Lim ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Nuclear Export ◽  
Low Dose ◽  
Performance Status ◽  
Cell Transplant ◽  
Weekly Schedule ◽  
Open Label ◽  
Phase 3 ◽  
Clinical Trial Registration ◽  
National Cooperative

TPS8055 Background: Len maintenance post ASCT is standard of care for patients (pts) with NDMM. Deep responses (CR or better) post ASCT correlates with better progression free survival (PFS). In a meta-analysis of len maintenance post ASCT (McCarthy PL et al. J Clin Oncol. 2017), only 10.7% of pts achieve CR post ASCT, and 72% of pts who discontinued len maintenance did so because of progressive disease (PD). Selinexor is a selective inhibitor of nuclear export that blocks exportin 1, thus retaining tumour suppressor proteins within the nucleus while blocking proto-oncoprotein translation. It is approved in combination with bortezomib and dexamethasone (dex) for pts with MM who have had at least 1 prior line of treatment, or with dex for pts with penta-refractory MM by the FDA. The oral bioavailability and weekly schedule of selinexor makes it suitable in combination with len for maintenance therapy. Given the encouraging activity (ORR 92%) and tolerability of selinexor, len and dex from the phase 1b/2 STOMP study, we hypothesise that combination low-dose selinexor and len (XR) will be well tolerated and effective, increasing CR and MRD negativity rate post ASCT, thus prolonging PFS compared to len. Methods: ALLG MM23 SeaLAND, is an ongoing randomised, multi-centre, phase 3 trial. Eligible pts ( > 17 years of age) have measurable disease, have undergone 3-6 cycles (C) of induction containing a proteasome inhibitor (PI) and/or immunomodulatory drug and recovered post melphalan-conditioned ASCT with adequate haematopoiesis, renal and liver function, and with ECOG performance status. Registration occurs prior to ASCT with screening between 75 to 115 days post ASCT. The study includes a lead-in safety phase of 20 patients with XR: Len 10mg daily days 1 to 21 and Selinexor 40mg weekly in a 28-day cycle. If well tolerated, Selinexor escalates to 60mg po weekly from C2 and Len to 15mg po daily from C4. Two safety reviews will occur after the 10th and 20th patients completes C2, respectively. Upon meeting safety criteria, a sample size of 290 pts will be randomised 1:1 to XR or lenalidomide (R). Therapy will continue until PD. The primary endpoint is PFS at 3 years post randomisation. Secondary endpoints include ORR and MRD-negativity rate (International Myeloma Working Group Response Criteria), PFS on next treatment line (PFS2), OS, safety and tolerability, quality of life, and cost effectiveness. Main analysis occurs after 232 patients complete 3-years of follow-up. Exploratory objective is to correlate immunological and molecular profiles to treatment response and resistance. ALLG MM23 SeaLAND is a multisite bi-national investigator-initiated trial lead by Australia and New Zealand’s national cooperative group, the Australasian Leukaemia & Lymphoma Group. Clinical trial registration: ACTRN12620000291987p. Clinical trial information: 12620000291987.

Sign in / Sign up

Export Citation Format

Share Document